168 related articles for article (PubMed ID: 35788405)
21. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
Acharya B; Frett B
Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
[TBL] [Abstract][Full Text] [Related]
22. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
23. Utility of
Jaleel J; Nasurudeen S; Babu AS; Gupta P; Khangembam BC; Patel C; Kumar R
Nucl Med Mol Imaging; 2023 Dec; 57(6):265-274. PubMed ID: 37982099
[TBL] [Abstract][Full Text] [Related]
24. Contrast-enhanced Interstitial Transpedal MR Lymphangiography for Thoracic Chylous Effusions.
Pieper CC; Feisst A; Schild HH
Radiology; 2020 May; 295(2):458-466. PubMed ID: 32208098
[TBL] [Abstract][Full Text] [Related]
25. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
[TBL] [Abstract][Full Text] [Related]
26. Predictive molecular pathology in metastatic thyroid cancer: the role of
Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
[TBL] [Abstract][Full Text] [Related]
27. Nontraumatic Chylothorax and Chylopericardium: Diagnosis and Treatment Using an Algorithmic Approach Based on Novel Lymphatic Imaging.
Gurevich A; Hur S; Singhal S; DiBardino D; Haas AR; Hansen-Flaschen JH; Nadolski G; Itkin M
Ann Am Thorac Soc; 2022 May; 19(5):756-762. PubMed ID: 34797746
[No Abstract] [Full Text] [Related]
28. Therapeutic effectiveness of diagnostic lymphangiography for refractory postoperative chylothorax and chylous ascites: correlation with radiologic findings and preceding medical treatment.
Kawasaki R; Sugimoto K; Fujii M; Miyamoto N; Okada T; Yamaguchi M; Sugimura K
AJR Am J Roentgenol; 2013 Sep; 201(3):659-66. PubMed ID: 23971461
[TBL] [Abstract][Full Text] [Related]
29. Treatment of symptomatic primary chylous disorders.
Noel AA; Gloviczki P; Bender CE; Whitley D; Stanson AW; Deschamps C
J Vasc Surg; 2001 Nov; 34(5):785-91. PubMed ID: 11700476
[TBL] [Abstract][Full Text] [Related]
30. Lymphatic interventions for isolated, iatrogenic chylous ascites: A multi-institution experience.
Majdalany BS; Khayat M; Downing T; Killoran TP; El-Haddad G; Khaja MS; Saad WA
Eur J Radiol; 2018 Dec; 109():41-47. PubMed ID: 30527310
[TBL] [Abstract][Full Text] [Related]
31. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract][Full Text] [Related]
32. Endolymphatic Interventions for the Treatment of Chylothorax and Chylous Ascites in Neonates: Technical and Clinical Success and Complications.
Srinivasa RN; Chick JFB; Gemmete JJ; Hage AN; Srinivasa RN
Ann Vasc Surg; 2018 Jul; 50():269-274. PubMed ID: 29524461
[TBL] [Abstract][Full Text] [Related]
33. [Chylous effusions].
Tomić I; Plavec G; Karlicić V; Spasić V; Rusović S; Stanić V; Cvijanović V; Ristanović A
Vojnosanit Pregl; 2003; 60(5):613-20. PubMed ID: 14608841
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
Rocco D; Sapio L; Della Gravara L; Naviglio S; Gridelli C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768754
[TBL] [Abstract][Full Text] [Related]
35. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis.
Ohara T; Oto T; Miyoshi K; Tao H; Yamane M; Toyooka S; Okazaki M; Date H; Sano Y
Ann Thorac Surg; 2008 Dec; 86(6):e7-8. PubMed ID: 19021963
[TBL] [Abstract][Full Text] [Related]
36. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
37. MRI Assessment of Chylous and Nonchylous Effusions: Use of Multipoint Dixon Fat Quantification.
Kuetting D; Luetkens J; Fimmers R; Sprinkart AM; Attenberger U; Pieper CC
Radiology; 2020 Sep; 296(3):698-705. PubMed ID: 32662762
[TBL] [Abstract][Full Text] [Related]
38. Interstitial Transpedal MR-Lymphangiography of Central Lymphatics Using a Standard MR Contrast Agent: Feasibility and Initial Results in Patients with Chylous Effusions.
Pieper CC; Schild HH
Rofo; 2018 Oct; 190(10):938-945. PubMed ID: 29665587
[TBL] [Abstract][Full Text] [Related]
39. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
40. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
Nguyen VQ; Geirnaert M
J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
